Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) have earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $48.00.

A number of research firms recently commented on COAG. HC Wainwright lifted their price objective on Hemab Therapeutics from $40.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Wedbush restated an “outperform” rating and set a $55.00 price target (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Jefferies Financial Group increased their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th.

Insider Transactions at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were acquired at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the transaction, the director owned 6,149,096 shares of the company’s stock, valued at $110,683,728. The trade was a 77.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 2,970,541 shares of company stock valued at $55,459,603 in the last quarter.

Hemab Therapeutics Stock Performance

Shares of NASDAQ:COAG opened at $47.31 on Friday. The company has a market cap of $2.21 billion and a price-to-earnings ratio of -1.97. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $52.15. The stock’s fifty day moving average is $32.30.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.